Skip to search formSkip to main contentSkip to account menu

brivanib alaninate

The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
Highly Cited
2013
Highly Cited
2013
PURPOSE The antiepidermal growth factor receptor monoclonal antibody cetuximab has improved survival in patients with metastatic… 
Highly Cited
2011
Highly Cited
2011
BACKGROUND This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in… 
Highly Cited
2010
Highly Cited
2010
Tumor angiogenesis is a complex and tightly regulated network mediated by various proangiogenic factors. The fibroblast growth… 
Highly Cited
2009
Highly Cited
2009
Fibroblast growth factor receptor-1 (FGFR-1) is amplified in 10% of human breast cancers. The goal of this study was to test the… 
2009
2009
PurposeBrivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development… 
Highly Cited
2008
Highly Cited
2008
Purpose: Hepatocellular carcinoma (HCC) is the fifth most common primary neoplasm; surgery is the only curative option but 5-year… 
Highly Cited
2008
Highly Cited
2008
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to… 
Highly Cited
2007
Highly Cited
2007
The process of neovascularization from preexisting blood vessels, referred to as angiogenesis, plays a critical role in both… 
Highly Cited
2005
Highly Cited
2005
  • Sumita RoyJ. Dey
  • Langmuir : the ACS journal of surfaces and…
  • 2005
  • Corpus ID: 19910993
Two N-acyl amino acid surfactants, sodium N-(11-acrylamidoundecanoyl)-glycinate (SAUG) and L-alaninate (SAUA), were synthesized…